---
title: Survival of patients with ruptured gastrointestinal stromal tumour treated
  with adjuvant imatinib in a randomised trial
date: '2024-06-11'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38862742/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240612181856&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: About one-fifth of ruptured GISTs treated with adjuvant
  imatinib did not recur during the first decade of follow-up. Relatively high OS
  rates were achieved despite ...'
disable_comments: true
---
CONCLUSIONS: About one-fifth of ruptured GISTs treated with adjuvant imatinib did not recur during the first decade of follow-up. Relatively high OS rates were achieved despite ...